{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:23:29Z","timestamp":1769081009697,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":541,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"British Heart Foundation Senior Clinical Research Fellowships","award":["FS\/SCRF\/20\/32005"],"award-info":[{"award-number":["FS\/SCRF\/20\/32005"]}]},{"name":"British Heart Foundation Senior Clinical Research Fellowships","award":["FS\/SCRF\/22\/32014"],"award-info":[{"award-number":["FS\/SCRF\/22\/32014"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The trials upon which recommendations for the use of cardiac resynchronization therapy (CRT) in heart failure used optimal medical therapy (OMT) before sodium-glucose co-transporter 2 inhibitors (SGLT2i). Moreover, the SGLT2i heart failure trials included only a small proportion of participants with CRT, and therefore, it remains uncertain whether SGLT2i should be considered part of OMT prior to CRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We compared electrocardiogram (ECG) and echocardiographic responses to CRT as well as hospitalization and mortality rates in consecutive patients undergoing implantation at a large tertiary centre between January 2019 to June 2022 with and without SGLT2i treatment. Three hundred seventy-four participants were included aged 74.0 \u00b1 11.5 years (mean \u00b1 standard deviation), with a left ventricular ejection fraction (LVEF) of 31.8 \u00b1 9.9% and QRS duration of 161 \u00b1 29 ms. The majority had non-ischaemic cardiomyopathy (58%) and were in NYHA Class II\/III (83.6%). These characteristics were similar between patients with (n = 66) and without (n = 308) prior SGLT2i treatment. Both groups demonstrated similar evidence of response to CRT in terms of QRS duration shortening, and improvements in LVEF, left ventricular end-diastolic inner-dimension (LVIDd) and diastolic function (E\/A and e\/e\u2032). While there was no difference in rates of hospitalization (for heart failure or overall), mortality was significantly lower in patients treated with SGLT2i compared with those who were not (6.5 vs. 16.6%, P = 0.049).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We observed an improvement in mortality in patients undergoing CRT prescribed SGLT2i compared with those not prescribed SGLT2i, despite similar degrees of reverse remodelling. The authors recommend starting SGLT2i prior to CRT implantation, where it does not delay implantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14784","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T21:48:58Z","timestamp":1713822538000},"page":"2314-2322","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Outcomes After Cardiac Resynchronization Therapy"],"prefix":"10.1093","volume":"11","author":[{"given":"Jonathan J.H.","family":"Bray","sequence":"first","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Coronelli","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam G.C.","family":"Scott","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Henry","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam S.","family":"Couch","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Ahmad","sequence":"additional","affiliation":[{"name":"UCL Medical School, University College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Ormerod","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Gamble","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Betts","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]},{"name":"Department of Cardiovascular Medicine, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lewis","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]},{"name":"Department of Cardiovascular Medicine, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver J.","family":"Rider","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]},{"name":"Department of Cardiovascular Medicine, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peregrine G.","family":"Green","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Herring","sequence":"additional","affiliation":[{"name":"Oxford Heart Centre, Oxford University Hospitals, NHS Trust , Oxford ,","place":["UK"]},{"name":"Department of Cardiovascular Medicine, University of Oxford , Oxford ,","place":["UK"]},{"name":"Department of Physiology, Anatomy and Genetics, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"2026012113141593400_ehf214784-bib-0001","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113141593400_ehf214784-bib-0002","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113141593400_ehf214784-bib-0003","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA)","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113141593400_ehf214784-bib-0004","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026012113141593400_ehf214784-bib-0005","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad141","article-title":"Improved prognosis after cardiac resynchronization therapy over a decade","volume":"25","author":"Leyva","year":"2023","journal-title":"Europace"},{"key":"2026012113141593400_ehf214784-bib-0006","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"2026012113141593400_ehf214784-bib-0007","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012113141593400_ehf214784-bib-0008","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113141593400_ehf214784-bib-0009","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113141593400_ehf214784-bib-0010","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Ev","year":"2007","journal-title":"BMJ"},{"key":"2026012113141593400_ehf214784-bib-0011","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012113141593400_ehf214784-bib-0012","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1210\/clinem\/dgab834","article-title":"Beneficial effect of sodium-glucose co-transporter 2 inhibitors on left ventricular function","volume":"107","author":"Shi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026012113141593400_ehf214784-bib-0013","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"2026012113141593400_ehf214784-bib-0014","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012113141593400_ehf214784-bib-0015","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrcardio.2017.139","article-title":"Reverse remodelling and myocardial recovery in heart failure","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026012113141593400_ehf214784-bib-0016","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/eurheartj\/ehm207","article-title":"Cardiac resynchronization therapy cures dyssynchronopathy in canine left bundle-branch block hearts","volume":"28","author":"Vernooy","year":"2007","journal-title":"Eur Heart J"},{"key":"2026012113141593400_ehf214784-bib-0017","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC: Basic Transl Sci"},{"key":"2026012113141593400_ehf214784-bib-0018","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2026012113141593400_ehf214784-bib-0019","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking Empagliflozin: the randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"2026012113141593400_ehf214784-bib-0020","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad059","article-title":"Timing of cardiac resynchronization therapy implantation","volume":"25","author":"Leyva","year":"2023","journal-title":"EP Europace"},{"key":"2026012113141593400_ehf214784-bib-0021","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/europace\/euaa411","article-title":"Optimized implementation of cardiac resynchronization therapy: A call for action for referral and optimization of care","volume":"23","author":"Mullens","year":"2021","journal-title":"Europace"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/4\/2314\/64526686\/eschf_11_4_2314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/4\/2314\/64526686\/eschf_11_4_2314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:15:59Z","timestamp":1769019359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/4\/2314\/8271206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,22]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14784","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"2023-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}